Similarly, a PRAME negative solid tumor model (BT474 breast carcinoma) exhibited a significantly lower uptake of 89Zr-DFO-MPA1 than the PRAME positive LNCaP-AR prostate cancer xenograft (Figure 6C and 6D; Table 2A and 2B). Here, AR is linked to prostate carcinoma.